Ikänik Farms, Inc. wholly owned Colombian subsidiary of the Company, Pideka SAS announced the results of its COVID-19 study conducted by a third party laboratory, using agronomically certified genetics cultivated in “Casa Flores”, the Pideka’s state-of-the-art cannabis camp located in Colombia.
“We are pleased to announce the results of our COVID- 19 study and the positive implications to the virus replication cycle,” said Brian Baca, CEO of Ikänik Farms. The company provided University of Antioquia’s (“UdeA”) Immunovirology Group with samples from multiple agronomically certified strains cultivated at Casa Flores. The analysis was conducted by “UdeA” and concluded the strains inhibited up to 62.5% of SARS-CoV-2.
The testing was conducted by UdeA’s Immunovirology Group in their A1 Biosafe laboratory to determine the antiviral activity of cannabinoids and the SARS-VoC-2 isolated virus. The University carried out two groups of experiments, following the international methodology used to determine the antiviral effect of compounds for the mitigation of SARS-CoV-2.
In the first group of experiments, the optimal dose of the derivatives in which the viability of healthy cells grown in VERO E6 culture medium obtained, was determined to be above international standards of 20% acceptance of cytotoxicity, experimentation with cannabis products, sought for 100% normal cell viability.
In the second group of experiments, the antiviral activity of cannabis derivatives on the SARS-CoV-2 virus was established, applying the preventive and optimal dose of the products obtained in the cytotoxicity experiments. Negative and positive controls were implemented, serving to correct the ANTIVIRAL effect of cannabis derivatives by plating testing. The SARS-CoV-2 viral titer was determined after treatment with cannabis, measuring the reduction resulting from the cannabis derivatives. The title obtained was 4.2×106 UFP (plate forming units) /mL. A microbiological test was also conducted on the provided samples and showed no presence of pathogenic fungi or bacteria, which is a requirement as set forth by European Pharmacopoeia, Europe’s legal and scientific benchmark for pharmacopoeia standards.
“We are excited to collaborate with UdeA, as the first academic institution in Colombia to isolate the virus. We will continue our research internationally in hopes to discover a viable cannabinoid solution for the current global crisis,” said Borja Sanz de Madrid, President of Ikänik International.
Universidad de Antioquia is a public university founded in 1803. Its main campus is located in the city of Medellín, Colombia; additionally, it has other campuses and facilities in the nine regions of the department of Antioquia, Colombia. The purpose of Universidad de Antioquia is to pursue, develop, and spread knowledge in the fields of humanities, science, arts, philosophy, and technology through research, teaching, and outreach activities. The university consists of 25 academic units divided into 14 faculties, four schools, four institutes, and three corporations that together offer around 130 undergraduate programs. Moreover, it offers 58 specializations, 46 medical specialties, 57 master’s programs, and 23 PhD programs, for a total of 184 graduate programs.
Ikanik Farms is creating a dynamic portfolio of cannabis brands aimed to support global pharmaceutical demand, rooted in health and wellness, action sports and unified with passion. The company’s leadership brings decades of expertise in R&D, cultivation, retail, branding, and corporate finance with the ambition to build the world’s most iconic, vertically integrated “seed-to-sale”, “MNO” Multi-National Operator. Ikänik Farms’ currently has operations located in California and Colombia, through its pharma division Pideka which holds both GMP_PHARMA and (GACP) Good Agricultural and Collection Practice certifications for the Casa Flores, operating facility.